Genetic testing

New Paper Highlights Clinical Utility of Natera’s Renasight™ Test in the Management of Kidney Disease

Retrieved on: 
Thursday, February 2, 2023
Health, Genetics, Health Technology, Other Health, Clinical Trials, Biotechnology, DNA, Kidney, Pediatrics, MSCE, Broad Institute, Augusta University Medical Center, Sickle cell disease, ADPKD, Diagnosis, Chronic kidney disease, Boston, Genetic testing, Polycystic kidney disease, National Kidney Foundation, Patient, Hospital, Nephrology, Harvard Medical School, The New England Journal of Medicine, NTRA, Associate, Medicine, Gene, Kidney disease, Manuscript, SCD, Pharmaceutical industry, Nursing, Natera, International Pediatric Nephrology Association, MD

This paper reviews the case of a 16-year-old patient with sickle cell disease (SCD) and kidney cysts.

Key Points: 
  • This paper reviews the case of a 16-year-old patient with sickle cell disease (SCD) and kidney cysts.
  • Natera’s Renasight test, a genetic testing panel that analyzes 385 genes related to kidney disease, was administered to examine whether an additional genetic cause may have been contributing to the patient’s kidney cysts.
  • The test identified genetic variants which led to a diagnosis of autosomal dominant polycystic kidney disease (ADPKD), in addition to the patient’s SCD.
  • Genetic testing is providing care teams with key insights that will better inform disease management and potentially slow disease progression for patients with kidney disease.”
    Chronic kidney disease affects more than 10% of the global population.

Assistive Reproductive Technology Innovations and Growth Opportunities 2023: Non-invasive PGT and AI-based Decision Support Creating Transformational Growth in IVF Procedures - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 26, 2023
General Health, Health, Technology, Artificial Intelligence, Software, Patent, PGT, Weakness, Artificial intelligence, SWOT, Pregnancy, IVF, Strategy, Genetic testing, Egg, ART, AI, Online shopping, Mineral oil, Growth

The "Assistive Reproductive Technologies: Innovations and Growth Opportunities" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Assistive Reproductive Technologies: Innovations and Growth Opportunities" report has been added to ResearchAndMarkets.com's offering.
  • Assisted reproductive technology (ART) includes advanced fertility treatments and procedures, such as the manipulation of eggs, sperm, or embryos to increase the chances of a successful pregnancy.
  • It highlights innovations around the pre-implantation genetic testing (PGT) of embryos and the use of artificial intelligence (AI) and predictive tools in IVF for improving clinical decision-making and outcomes.
  • A strength, weakness, opportunities, and threats (SWOT) analysis of the PGT and AI technology segments has also been offered, as well as a future outlook of each technology.

Unilabs and Ambry Sign Agreement to Enhance Genetic Testing Services for Biopharma Companies in Europe, Latin America and the Middle East

Retrieved on: 
Thursday, January 26, 2023
Health, Genetics, General Health, Research, Science, Pharmaceutical, Biotechnology, Physician, Radiology, Forest Law Enforcement and Governance Program, Drug development, CARE, Patient, Education, Risk, Partnership, Genomics, Genetic testing, Multimedia, Chief medical informatics officer, Hospital Insurance and Diagnostic Services Act, Medical imaging, Pharmaceutical industry, Unilab, Ambry

Unilabs , a leading diagnostic services provider, and Ambry Genetics (Ambry), a leader in clinical diagnostic testing and a subsidiary of REALM IDx , have entered an exclusive partnership to enhance high-quality genetic testing services for government-sponsored and biopharma companies conducting international clinical trials and research.

Key Points: 
  • Unilabs , a leading diagnostic services provider, and Ambry Genetics (Ambry), a leader in clinical diagnostic testing and a subsidiary of REALM IDx , have entered an exclusive partnership to enhance high-quality genetic testing services for government-sponsored and biopharma companies conducting international clinical trials and research.
  • View the full release here: https://www.businesswire.com/news/home/20230126005123/en/
    Ambry will use Unilabs’ genomic lab services and variant interpretation capabilities in Europe, Latin America and the Middle East – regions where Ambry does not have a physical presence.
  • Unilabs will also provide genetic evaluation and patient cohort recruitment for clinical trials and patient identification and stratification for targeted treatments.
  • “Together with our industry-leading clinical laboratory, radiology and digital pathology services, we provide access to a test menu of more than 4,000 genetic tests.

Global In-Vitro Fertilization Services Markets, 2022-2023 & 2027 - Current Market Scenario, Latest Technologies, Costs, and Future Growth Opportunities - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 25, 2023
Health, Consumer, Other Health, Baby, Maternity, General Health, Biotechnology, Growth, IVF, Patient, Genetic testing, Egg, Infertility, ART, Fertilisation, Artificial intelligence, Birth control

The "Global in Vitro Fertilization Services Growth Opportunities" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global in Vitro Fertilization Services Growth Opportunities" report has been added to ResearchAndMarkets.com's offering.
  • The study analyzes the key factors driving and restraining growth and identifies the key growth opportunities emerging from this space for market players and stakeholders to leverage.
  • This study analyzes the in vitro fertility (IVF) services market across the globe.
  • The study provides a global overview of the market with a focus on the current market scenario, the latest technologies, costs, and future growth opportunities.

Global Prenatal and New-born Genetic Testing Market Report 2022 to 2027: Players Include Agilent Technologies, AutoGenomics, Baebies and Berry Genomics - ResearchAndMarkets.com

Retrieved on: 
Monday, January 23, 2023
Medical Devices, Hospitals, Neurology, Science, Genetics, Nursing, Medical Supplies, Consumer, Biotechnology, Health, Other Science, Research, Other Health, Parenting, Pharmaceutical, Baby, Maternity, Oncology, Investment, Emotion, Ansoff matrix, COVID-19, Market development, Geography, Porter's five forces analysis, Impact, Genetic testing, SWOT, Risk, USD, Growth, Observation, Dietary supplement, Marketing, Retail, Risk management

The "Global Prenatal and New-born Genetic Testing Market (2022-2027) by Type, Technology, Application, and Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Prenatal and New-born Genetic Testing Market (2022-2027) by Type, Technology, Application, and Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.
  • The report presents a detailed Ansoff matrix analysis for the Global Prenatal and New-born Genetic Testing Market.
  • The analyst analyses the Global Prenatal and New-born Genetic Testing Market using the Ansoff Matrix to provide the best approaches a company can take to improve its market position.
  • The report offers a comprehensive evaluation of the Global Prenatal and New-born Genetic Testing Market.

Thermo Fisher Scientific Launches CE-IVD Marked Assay to Detect Treatment-Resistant Strains of HIV-1

Retrieved on: 
Tuesday, January 24, 2023
Health, Manufacturing, Other Science, Research, Other Manufacturing, Science, Biotechnology, HIV, Genetic testing, Equitable, Thermo Fisher Scientific, HIV-1, UNAIDS, Plasma, RNA, Vaccine, Pharmaceutical industry

Thermo Fisher Scientific, the world leader in serving science, today announced the launch of its CE-IVD marked Applied Biosystems TaqPath Seq HIV-1 Genotyping Kit, a Sanger sequencing-based assay that examines positive samples of human immunodeficiency virus (HIV) to identify genetic variants that may resist common antiretroviral therapeutics.

Key Points: 
  • Thermo Fisher Scientific, the world leader in serving science, today announced the launch of its CE-IVD marked Applied Biosystems TaqPath Seq HIV-1 Genotyping Kit, a Sanger sequencing-based assay that examines positive samples of human immunodeficiency virus (HIV) to identify genetic variants that may resist common antiretroviral therapeutics.
  • Antiretroviral drug resistance testing is needed since greater than 10% of treatment-naïve adults, and about half of newly diagnosed infants, show resistance to first-line drug classes.
  • “Resistance to antiretroviral therapy is an important concern when providing care to people living with HIV,” said Dr. Manoj Gandhi, senior medical director of genetic testing solutions at Thermo Fisher Scientific.
  • Equitable pricing is available to eligible customers through Thermo Fisher’s Global Health Equity program.

BioAro is the first Canadian company to launch comprehensive genetic testing panels for various heart diseases

Retrieved on: 
Thursday, February 9, 2023
Medicine, Splenic infarction, Athlete, Heart, Dilated cardiomyopathy, Genetic testing, Multimedia, Physician, Facial muscles, Heart failure, Risk, AB, Genetics, Blood pressure, GMP, Hypercholesterolemia, Kidney, Blood, Artery, Diagnosis, Cardiac arrest, Patient, Cardiology, IHD, Skin, Sport, Arrhythmogenic cardiomyopathy, Gene, Environment, Ageing, Woman, Arrest, Cardiovascular disease, Parent, Hypertension, Stroke, Dietary supplement, Pharmaceutical industry, Medical device, Vaccine

Almost 1 in 3 Canadians are touched by heart failure, and over 100,000 new Canadians are diagnosed with heart failure every year.

Key Points: 
  • Almost 1 in 3 Canadians are touched by heart failure, and over 100,000 new Canadians are diagnosed with heart failure every year.
  • February is known as International Heart month in order to raise awareness about the various heart conditions and create ways to help in reducing the mortality rate caused due to heart diseases.
  • BioAro is taking an initiative to launch the genetic testing of targeted panels for heart disease conditions using high-throughput next generation sequencing technique.
  • Heart Failure: Heart failure is a chronic, progressive condition in which your heart muscle can't pump enough blood to meet your body's needs all the time.

Experiences of Black Women With Breast Cancer Highlight Need for Better Care, Improved Outcomes

Retrieved on: 
Friday, February 3, 2023
BRCA, Woman, Health equity, Susan, Treatment, Human, Breast cancer, Patient, Health, Risk, Survivor, Health care, Disease, Education, Breast, Genetic testing, Cancer, Birth control, Nursing, Diagnosis, Black

DALLAS, Feb. 3, 2023 /PRNewswire/ -- In the United States, breast cancer affects Black women and white women in extremely different ways. White women are more likely to be diagnosed with the disease overall, however, Black women are more likely to have aggressive types of breast cancer and are 40 percent more likely to die from it. Since the founding of Susan G. Komen®, the world's leading breast cancer organization four decades ago, much progress in detecting and treating breast cancer has been made. Yet, inequities in care, treatment and outcomes between Black and white women with the disease remain. This is unacceptable.

Key Points: 
  • White women are more likely to be diagnosed with the disease overall, however, Black women are more likely to have aggressive types of breast cancer and are 40 percent more likely to die from it.
  • Since the founding of Susan G. Komen ®, the world's leading breast cancer organization four decades ago, much progress in detecting and treating breast cancer has been made.
  • Black women often have aggressive types of breast cancer and are 40% more likely to die from it.
  • Breast cancer does not run in Monique's family, yet through genetic testing , she learned she carries a genetic mutation that increases her risk of breast cancer.

OVARIAN CANCER LEADERS URGE GENETIC TESTING FOR INCREASED-RISK INDIVIDUALS, AND CONSIDERATION OF PROPHYLACTIC SURGERY FOR ALL WOMEN

Retrieved on: 
Wednesday, February 1, 2023
Society, Gynecologic Oncology (journal), Ovarian cancer, Science, Woman, Learning, OCRA, United Kingdom, Breast, Society of Gynecologic Oncology, Cancer, Salpingectomy, Patient, Ovarian Cancer Research Alliance, News, Research, Mortality, Risk, Tubing (recreation), Weapon, Risk management, Genetic testing, Multimedia, Gynecologic cancer disparities in the United States, Ovary, Mount Sinai Health System, MD, Birth control, Pharmaceutical industry

Until there is a cure, these are our best weapons in the battle against ovarian cancer.

Key Points: 
  • Until there is a cure, these are our best weapons in the battle against ovarian cancer.
  • "Ovarian cancer is considered a rare disease, but for those with a family history and/or genetic mutation, the risk jumps to 40-50% or even higher.
  • "This is incredibly hard information to accept and runs contrary to almost all messaging related to ovarian cancer awareness to date.
  • However, to ignore learnings gained from current research would be detrimental to the wellbeing of women and the future of ovarian cancer research," said Moran.